Intravitreal bevacizumab in cystoid macular edema associated to maternally inherited diabetes and deafness's macular dystrophy.

Autor:	Marco-Campmany A; Department of Ophthalmology, Hospital Universitario de La Ribera, Alzira, Spain., Pacheco-Cervera J; Department of Ophthalmology, Hospital Universitario de La Ribera, Alzira, Spain., Navarrete-Sanchis J; Department of Ophthalmology, Hospital Universitario de La Ribera, Alzira, Spain., Tomás-Torrent JM; Department of Ophthalmology, Hospital Universitario de La Ribera, Alzira, Spain., García-Canet S; Department of Ophthalmology, Hospital Universitario de La Ribera, Alzira, Spain., Cuadrado-Gómez T; Department of Ophthalmology, Hospital Universitario de La Ribera, Alzira, Spain.
Jazyk:	angličtina
Zdroj:	European journal of ophthalmology [Eur J Ophthalmol] 2020 Oct 30, pp. 1120672120969034. Date of Electronic Publication: 2020 Oct 30.
DOI:	10.1177/1120672120969034
Abstrakt:	Introduction: Maternally inherited diabetes and deafness (MIDD) is a rare and infradiagnosed cause of diabetes which can, in a high number of cases, associate a macular dystrophy. Case Presentation: We report the case of a 49- year-old man affected of this syndrome, with proven m3243G>A mitochondrial mutation, who developed macular cysts 20 years after the initial presentation of his macular dystrophy. The fluorescein angiography showed no leakage, ruling out a diabetic macular edema. A treatment with intravitreal bevacizumab led to cystic changes resolution and visual acuity recovery. Conclusion: Intravitreal bevacizumab can be successfully employed for this complication of MIDD's macular dystrophy.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu